KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) – Equities research analysts at HC Wainwright issued their Q1 2024 earnings estimates for KalVista Pharmaceuticals in a report issued on Monday, July 10th. HC Wainwright analyst A. Fein expects that the specialty pharmaceutical company will post earnings per share of ($0.73) for the quarter. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.07) per share. HC Wainwright also issued estimates for KalVista Pharmaceuticals’ Q3 2024 earnings at ($0.79) EPS, Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($2.62) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($2.08) EPS, FY2027 earnings at ($1.88) EPS and FY2028 earnings at ($1.17) EPS.
A number of other analysts also recently weighed in on KALV. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, April 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 11th.
KalVista Pharmaceuticals Stock Performance
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) last posted its quarterly earnings data on Friday, July 7th. The specialty pharmaceutical company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.10.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in KALV. Rhumbline Advisers boosted its stake in shares of KalVista Pharmaceuticals by 3.3% in the 1st quarter. Rhumbline Advisers now owns 38,822 shares of the specialty pharmaceutical company’s stock valued at $305,000 after buying an additional 1,237 shares during the period. Alliancebernstein L.P. raised its holdings in shares of KalVista Pharmaceuticals by 13.0% in the third quarter. Alliancebernstein L.P. now owns 17,064 shares of the specialty pharmaceutical company’s stock worth $248,000 after acquiring an additional 1,964 shares during the last quarter. Point72 Hong Kong Ltd acquired a new position in shares of KalVista Pharmaceuticals in the second quarter worth $26,000. Price T Rowe Associates Inc. MD increased its stake in KalVista Pharmaceuticals by 14.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 20,999 shares of the specialty pharmaceutical company’s stock valued at $207,000 after purchasing an additional 2,672 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in KalVista Pharmaceuticals by 24.9% during the first quarter. JPMorgan Chase & Co. now owns 13,424 shares of the specialty pharmaceutical company’s stock worth $198,000 after acquiring an additional 2,677 shares during the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, CFO Benjamin L. Palleiko sold 4,037 shares of the firm’s stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $10.14, for a total transaction of $40,935.18. Following the sale, the chief financial officer now owns 78,126 shares of the company’s stock, valued at approximately $792,197.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Benjamin L. Palleiko sold 4,037 shares of KalVista Pharmaceuticals stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $10.14, for a total value of $40,935.18. Following the completion of the sale, the chief financial officer now directly owns 78,126 shares in the company, valued at $792,197.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher Yea sold 2,604 shares of the business’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $10.14, for a total transaction of $26,404.56. Following the completion of the transaction, the insider now owns 37,310 shares of the company’s stock, valued at $378,323.40. The disclosure for this sale can be found here. Insiders have sold a total of 12,268 shares of company stock valued at $124,398 over the last three months. 8.30% of the stock is owned by company insiders.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Featured Stories
- Five stocks we like better than KalVista Pharmaceuticals
- Contrarian Play: Beyond Meat Is At An Inflection Point
- Alibaba Just Flashed Green, Very Green
- This Small Cap Stock Surged Over 100%
- The CPI Data Isn’t As Good As You Think It Is
- How to Invest in Gold and Silver
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
